Investegate |Idorsia Pharmaceuticals Ltd Announcements | Idorsia Pharmaceuticals Ltd: Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal

Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal
Allschwil, Switzerland – February 2, 2021
Idorsia Ltd (SIX: IDIA) today reported the results of an arbitration proceeding between Actelion Ltd (“Actelion”) and the assignee of certain former Axovan shareholders (the “Claimant”) claiming that the acquisition of Actelion by Johnson & Johnson and/or the Demerger triggered the accelerated payment of all outstanding milestones mainly relating to clazosentan (the “Claim”).
Idorsia was notified that the Claim had been dismissed by the Arbitral Tribunal in its final award dated February 1, 2021.
Idorsia remains fully committed to developing and commercializing clazosentan and to paying any milestones, if and when due.

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,Swiss ,Andrewc Weiss , ,Idorsia Ltd ,Head Of Investor Relations Corporate Communications ,Actelion Ltd ,Idorsia Pharmaceuticals Ltd ,Swiss Exchange ,Johnson ,Arbitral Tribunal ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,சுவிட்சர்லாந்து ஜநரல் ,சுவிட்சர்லாந்து ,சுவிஸ் ,தலை ஆஃப் முதலீட்டாளர் உறவுகள் பெருநிறுவன தகவல்தொடர்புகள் ,சுவிஸ் பரிமாற்றம் ,ஜான்சன் ,நடுவர் தீர்ப்பாயம் ,துணை ப்ரெஸிடெஂட் ,முதலீட்டாளர் உறவுகள் ,மருந்துகள் லிமிடெட் ,